Here are three things to know:
1. MagnetOs Putty received FDA 510(k) clearance in August 2017 as an autograft extender in the posterolateral spine.
2. While MagnetOs Putty must be used with autograft as a bone graft extender in the posterolateral spine, it is intended for standalone use in the extremities and pelvis.
3. MagnetOs Putty is intended to fill bony voids or skeletal system gaps. It is designed to resorb and be replaced with bone during the healing process.
More articles on biologics:
5 things to know about Carmell Therapeutics
Global spinal biologics market to exceed $2.36B by 2021: 3 findings
Anika Therapeutics resumes distribution of cartilage regeneration treatments
